After deciding that tirzepatide was no longer in short supply, the FDA removed it from the official list ... FDA changed its status via a post on its website on 2nd October based on statements ...
During your consultation, a medical team reviews your health history to personalize GLP-1 weight loss treatments, including options like semaglutide, Mounjaro, Ozempic, or Zepbound ... of positive ...
Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr.
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...
The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback